Significant fatigue or weakness that interferes with daily activities
With tirzepatide, the usual starting dose is 2.5 mg once weekly, with increases every ~4 weeks if tolerated, up to a maintenance dose of 5-15 mg weekly for weight loss
In phase III: Semaglutide 2.4 mg (STEP-1): nausea 44.2%, diarrhea 31.5%, vomiting 24.8% Tirzepatide 15 mg (SURMOUNT-1): nausea 29.2%, diarrhea 23.0%, constipation 16.8% Retatrutide 12 mg (TRIUMPH-1): nausea 37.2%, vomiting 22.0%, diarrhea 27.1% Key observation: tirzepatide shows the most favorable GI profile at equivalent dose, likely tied to the GIP component dampening GLP-1-mediated nausea signaling at the brainstem level
doi: 10.1111/jfbc.13359 123 SauerHWartenbergMHeschelerJ
Its important to work closely with your healthcare provider to address any issues and optimize your treatment for the best results.
Instead of rushing through your digestive system, food stays in your stomach longer